The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming
Open accessAbstract
Introduction: Snakebite is an urgent, unmet global medical need causing significant morbidity and mortality worldwide. Varespladib is a potent inhibitor of venom secretory phospholipase A2 (sPLA2) that can be administered orally via its prodrug, varespladib-methyl. Extensive preclinical data support clinical evaluation of varespladib as a treatment for snakebite envenoming (SBE). The protocol reported here was designed to evaluate varespladib-methyl for SBE from any snake species in multiple geographies. Methods and Analysis: BRAVO (Broad-spectrum Rapid Antidote: Varespladib Oral for snakebite) is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study to evaluate the safety, tolerability, and efficacy of oral varespladib-methyl plus standard of care (SoC) vs. SoC plus placebo in patients presenting with acute SBE by any venomous snake species. Male and female patients 5 years of age and older who meet eligibility criteria will be randomly assigned 1:1 to varespladib-methyl or placebo. The primary outcome is the Snakebite Severity Score (SSS) that has been modified for international use. This composite outcome is based on the sum of the pulmonary, cardiovascular, nervous, hematologic, and renal systems components of the updated SSS. Ethics and Dissemination: This protocol was submitted to regulatory authorities in India and the US. A Clinical Trial No Objection Certificate from the India Central Drugs Standard Control Organisation, Drug Controller General-India, and a Notice to Proceed from the US Food and Drug Administration have been obtained. The study protocol was approved by properly constituted, valid institutional review boards or ethics committees at each study site. This study is being conducted in compliance with the April 1996 ICH Guidance for Industry GCP E6, the Integrated Addendum to ICH E6 (R2) of November 2016, and the applicable regulations of the country in which the study is conducted. The trial is registered on Clinical trials.gov, NCT#04996264 and Clinical Trials Registry-India, 2021/07/045079 000062.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Additionally, clinical trials (Phase II clinical trials) have demonstrated that oral varespladib methyl is safe and well tolerated as an adjunct to antivenom”
From Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 1×
“SPIRIT reporting guidelines were applied to trial design, Supplemental Table S4 [35].”
MethodThe clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,760
Gutiérrez, J. M., Calvete, J. J., Habib, A. G., Harrison, R. A., Williams, D. J., & Warrell, D. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.63 · Cited by 955
Snake-bites: appraisal of the global situation.
Chippaux, J. (1998) · Europe PMC (PubMed Central) · Cited by 932
Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes
Manjunatha Kini, R. (2003) · Toxicon · doi:10.1016/j.toxicon.2003.11.002 · Cited by 720
Snakebite Mortality in India: A Nationally Representative Mortality Survey
Mohapatra, B., Warrell, D. A., Suraweera, W., Bhatia, P., Dhingra, N., Jotkar, R. M., Rodriguez, P. S., Mishra, K., Whitaker, R., Jha, P., et al. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001018 · Cited by 661 · cited 1×
“An estimated 75 percent of deaths from SBE occur outside the hospital setting before victims can reach adequate medical care [3,4] and poor outcomes are associated with delays in care [5–7].”
BackgroundA Review and Database of Snake Venom Proteomes
Tasoulis, T., & Isbister, G. (2017) · Toxins · doi:10.3390/toxins9090290 · Cited by 616
Williams, D. J., Faiz, M. A., Abela-Ridder, B., Ainsworth, S., Bulfone, T. C., Nickerson, A. D., Habib, A. G., Junghanss, T., Fan, H. W., Turner, M., et al. (2019) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007059 · Cited by 447 · cited 5×
“The WHO’s Snakebite Envenoming Working Group stated that “accelerating preclinical and clinical testing of promising prehospital adjunctive treatments, such as the phospholipase A2 inhibitor varespladib or varespladib-methyl, as part of the WHO snake bite envenoming research agenda may lead to early improvements in pr…”
BackgroundInfluentialVulnerability to snakebite envenoming: a global mapping of hotspots
Longbottom, J., Shearer, F. M., Devine, M., Alcoba, G., Chappuis, F., Weiss, D. J., Ray, S. E., Ray, N., Warrell, D. A., Ruiz de Castañeda, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31224-8 · Cited by 366
Cited by
Bittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
“A https://doi.org/10.1038/s42003-024-06019-6 clinical trial is underway to test this oral inhibitor in snakebite envenoming 168 .”
BackgroundInfluentialModulation of immunity by the secreted phospholipase A2 family
Murakami, M., Sato, H., & Taketomi, Y. (2023) · Immunological Reviews · doi:10.1111/imr.13205 · Cited by 67
A global core outcome measurement set for snakebite clinical trials
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B. K., Mwalukore, S., Alphan, H. J., Aggarwal, D., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00479-x · Cited by 41
Self-citationProgress and Challenges in the Field of Snakebite Envenoming Therapeutics
Gutiérrez, J. M., Casewell, N. R., & Laustsen, A. H. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022024-033544 · Cited by 48
Clare, R. H., Dawson, C. A., Westhorpe, A., Albulescu, L.-O., Woodley, C. M., Mosallam, N., Chong, D. J. W., Kool, J., Berry, N. G., O’Neill, P. M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328950 · Cited by 43
Metadata
- Authors
- Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., Manikath, N., Platts-Mills, T. F., & Lewin, M. R.
- Affiliations
- Infraredx, Inc. (United States) (US)
- Duke University (US)
- Sardar Patel Medical College (IN)
- Mysore Medical College (IN)
- Calcutta National Medical College and Hospital (IN)
- University of Arizona (US)
- University of Kentucky (US)
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
- Post Graduate Institute of Medical Education and Research (IN)
- Government Medical College (IN)
- Ophirex, Inc., Corte Madera, CA 94295, USA
- Corresponding author
- Lewin, Matthew R.
- ORCID
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2022-12-28
- Volume
- 15
- Issue
- 1
- Pages
- 22
- ISSN
- 2072-6651 (ISSN-L)
- PMC
- PMC9862656
- OpenAlex
- W4313327570
- Cited by
- 39
- References
- 54
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 17 · 2023: 13
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Toxins (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UA Campus Repository (The University of Arizona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Defense Health Agency (W81XWH20C0017, 222964/Z/21/Z)
- Wellcome Trust (W81XWH20C0017, 222964/Z/21/Z)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Venomous Animal Envenomation and Studies
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Amphibian and Reptile Biology
- Keywords
- snakebite, venomous snakes, safety and tolerability, standard of care
- MeSH terms
- Acetates, Female, Humans, Indoles, Keto Acids, Male, Nitriles, Snake Bites, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Phospholipases A2, Secretory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming. https://app.cochat.ai/papers/10.3390/toxins15010022
- The paper
- Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., Manikath, N., Platts-Mills, T. F., & Lewin, M. R. (2022). The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming. Toxins. https://doi.org/10.3390/toxins15010022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.